ReviewCureus2025
Clinical Characteristics of Gait Disturbance in Charcot-Marie-Tooth Disease and Future Directions in Physical Therapy.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PDXK-Related Neuropathy: A Case With a Novel Splice-Altering Missense Variant and Literature Review.Molecular genetics & genomic medicine · 2026Review
- A comparative phenotypic analysis of a heterogeneous PMP22 cohort presenting with persistent toe-walking versus classic PMP22-related Neuropathies.Global medical genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Charcot-Marie-Tooth disease (CMT) is a hereditary and progressive peripheral neuropathy affecting both motor and sensory nerves. It is among the most common inherited neuropathies and is primarily classified into demyelinating (type 1) and axonal (type 2) forms based on motor nerve conduction velocity, with over 100 genetic subtypes identified. Due to this genetic and clinical heterogeneity, the onset, severity, and degree of motor and sensory impairments vary widely among individuals. One of the hallmark manifestations of CMT is gait disturbance. As the disease progresses, individuals often develop foot drop and foot deformities such as pes cavus and equinus, leading to a significant decline in gait function. This results in limitations in activities of daily living, increased risk of falls, reduced social participation, and decreased quality of life. Currently, no curative treatment exists for CMT. Management focuses on symptomatic interventions, including orthotic support, surgical procedures, and physical therapy. While physical therapy may improve muscle strength and physical function, the quality of evidence remains moderate, and no standardized rehabilitation protocols have been firmly established. Tailored physical therapy programs are considered essential for effective intervention. Given these challenges, the need for quantitative and objective assessment of gait disturbances in CMT has become increasingly important. Conventional clinical scales, such as the CMT Neuropathy Score, rely heavily on subjective grading and offer limited value in detailed gait analysis. In contrast, recent advances in motion analysis - such as three-dimensional gait analysis, ground reaction force measurement, and wearable sensors - have provided more precise assessments. However, issues related to standardization and clinical applicability remain unresolved. This review aims to summarize the neuropathology and clinical characteristics of gait disturbances in CMT, discuss current gait assessment methodologies, explore physical therapy strategies, and highlight the need for quantitative evaluation and future research directions in rehabilitation for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.